Argus retinal prosthesis

Last updated

Visual processing through a bionic eye Visual Processing Through Bionic Eye.svg
Visual processing through a bionic eye

Argus retinal prosthesis, also known as a bionic eye, is an electronic retinal implant manufactured by the American company Second Sight Medical Products. It is used as a visual prosthesis to improve the vision of people with severe cases of retinitis pigmentosa. The Argus II version of the system was approved for marketing in the European Union in March 2011, and it received approval in the US in February 2013 under a humanitarian device exemption. The Argus II system costs about US$150,000, excluding the cost of the implantation surgery and training to learn to use the device. Second Sight had its IPO in 2014 and was listed on Nasdaq. [1]

Contents

Production and development of the prosthesis was discontinued in 2020, [2] but taken over by the company Cortigent in 2023. [3]

Medical use

The Argus II is specifically designed to treat people with retinitis pigmentosa. [4] The device was approved with data from a single-arm clinical trial that enrolled thirty people with severe retinitis pigmentosa; the longest follow-up on a trial subject was 38.3 months. [4] People in the trial received the implant in only one eye and tests were conducted with the device switched on, or switched off as a control. [5] With the device switched on, about 23% of the subjects had improvements in their ability to see; all had been at 2.9 or higher on the LogMAR scale and improvements ranged from just under 2.9 to 1.6 LogMAR – the equivalent of 20/1262 reading ability. [4] [5] : 18  96% of the subjects were better able to identify a white square on a black computer screen; 57% were more able to determine the direction in which a white bar moved across a black computer screen. With the device switched on, about 60% were able to accurately walk to a door that was 20 feet away, as opposed to only 5% with the device switched off; 93% had no change in their perception of light. [5] : 18 

Side effects

Among the thirty subjects in the clinical trial, there were nine serious adverse events recorded, including lower than normal intraocular pressure, erosion of the conjunctiva, reopening of the surgical wound, inflammation inside the eye, and retinal detachments. [4] [5] : 19  There is also a risk of bacterial infection from the implanted cables that connect the implant to the signal processor. [4]

Surgical procedure

The implantation procedure takes several hours, with the person receiving the implant under general anaesthesia. The surgeon removes the vitreous humor and any membranes on the retina where the implant will be placed. The implant is attached to the surface of the retina with a tack. The cables connecting the implant to the processor are run through the pars plana, a region near where the iris and sclera touch. [5]

Device

The Argus implant's primary external element is a digital camera mounted on eyeglass frames, which obtains images of the user's surroundings; signals from the camera are transmitted wirelessly to a computerised image processor. The processor is in turn connected by cables to the implant itself, which is surgically implanted on the surface of the person's retina and tacked into place. The implant consists of 60 electrodes, each 200 microns in diameter. [4] [6]

The resolution of the 6 dot by 10 dot rectangular grid image (produced by the 6 by 10 array of 60 electrode, of which 55 are enabled ) in a person's vision is very low relative to normal visual acuity. This allows visual detection of edges of large areas of high contrast, such as door frames and sidewalks, to give the individual the capability to navigate in their environment more safely. [7]

History

The implant's manufacturer, Second Sight Medical Products, was founded in Sylmar, California, in 1998, by Alfred Mann, Samuel Williams, and Gunnar Bjorg. [8] Williams, an investor in a cochlear implant company operated by Mann, approached Mann about founding a company to develop a similar product for the eye, and Mann called a meeting with the two of them and Robert Greenberg, who worked at Mann's foundation. [9] Greenberg had previously worked on retinal prosthetics as a graduate student at Johns Hopkins University, wrote the business plan, and was appointed as CEO of the new company when it was launched. [10] Greenberg led the company as CEO through 2015 (and was chairman of the board through 2018). The first version of the prosthesis, the Argus I, was clinically tested on six people starting in 2002. [11] The second version, the Argus II, was designed to be smaller and easier to implant, and was co-invented by Mark Humayun of the USC Eye Institute, who had been involved in the clinical testing of the Argus I. [12] [11] The Argus II was first tested in Mexico in 2006, and then a 30-person clinical trial was conducted in 10 medical centers across Europe and the United States. [9] [11]

Society and culture

Regulatory status

The Argus II received approval for commercial use in the European Union in March 2011. [13] In February 2013, the FDA approved the Argus II under a humanitarian device exemption, authorizing its use for up to 4,000 people in the US per year. [4] [14] [15]

Pricing and insurance

The Argus II was initially available at a limited number of clinics in France, Germany, Italy, the Netherlands, the United Kingdom and Saudi Arabia, at an EU market price of US$115,000. [13] When the Argus II launched in the United States in February 2013, Second Sight announced that it would be priced at around $150,000, excluding the cost of surgery and usage training. [16] In August 2013, Second Sight announced that reimbursement payments had been approved for the Argus II for blind Medicare recipients in the United States. [17]

Research

A trial in England funded by NHS England for ten patients began in 2017. [18]

Aftermath

In 2020, Second Sight stopped providing technical support for the Argus, as well as for the successor device, Argus II, and for the brain implant, Orion; an investigation by IEEE Spectrum revealed that users risk – and in some cases, have already experienced – a return to blindness. [2] Second Sight merged with Nano Precision Medical in August 2023 [19] with a commitment to provide technical support for the Argus II. [20]

See also

Related Research Articles

<span class="mw-page-title-main">Retinitis pigmentosa</span> Gradual retinal degeneration leading to progressive sight loss

Retinitis pigmentosa (RP) is a member of a group of genetic disorders called inherited retinal dystrophy (IRD) that cause loss of vision. Symptoms include trouble seeing at night and decreasing peripheral vision. As peripheral vision worsens, people may experience "tunnel vision". Complete blindness is uncommon. Onset of symptoms is generally gradual and often begins in childhood.

<span class="mw-page-title-main">Macular edema</span> Medical condition

Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye and causes it to thicken and swell (edema). The swelling may distort a person's central vision, because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail, form, and color that is directly in the centre of the field of view.

<span class="mw-page-title-main">Electroretinography</span>

Electroretinography measures the electrical responses of various cell types in the retina, including the photoreceptors, inner retinal cells, and the ganglion cells. Electrodes are placed on the surface of the cornea or on the skin beneath the eye to measure retinal responses. Retinal pigment epithelium (RPE) responses are measured with an EOG test with skin-contact electrodes placed near the canthi. During a recording, the patient's eyes are exposed to standardized stimuli and the resulting signal is displayed showing the time course of the signal's amplitude (voltage). Signals are very small, and typically are measured in microvolts or nanovolts. The ERG is composed of electrical potentials contributed by different cell types within the retina, and the stimulus conditions can elicit stronger response from certain components.

Neuroprosthetics is a discipline related to neuroscience and biomedical engineering concerned with developing neural prostheses. They are sometimes contrasted with a brain–computer interface, which connects the brain to a computer rather than a device meant to replace missing biological functionality.

The Lions Eye Institute (LEI) is an Australian medical research institute affiliated with the University of Western Australia. It was established in 1983 with support of the Lions Clubs of Western Australia and headquartered in the Perth suburb of Nedlands, Western Australia. The LEI is a not-for-profit centre of excellence that combines an ophthalmic clinic with scientific discovery developing techniques for the prevention of blindness and the reduction of pain from blinding eye conditions.

<span class="mw-page-title-main">Retinal implant</span>

A retinal implant is a visual prosthesis for restoration of sight to patients blinded by retinal degeneration. The system is meant to partially restore useful vision to those who have lost their photoreceptors due to retinal diseases such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD). Retinal implants are being developed by a number of private companies and research institutions, and three types are in clinical trials: epiretinal, subretinal, and suprachoroidal. The implants introduce visual information into the retina by electrically stimulating the surviving retinal neurons. So far, elicited percepts had rather low resolution, and may be suitable for light perception and recognition of simple objects.

<span class="mw-page-title-main">Retinitis</span> Medical condition

Retinitis is inflammation of the retina in the eye, which can permanently damage the retina and lead to blindness. The retina is the eye's "sensing" tissue. Retinitis may be caused by a number of different infectious agents. Its most common form, called retinitis pigmentosa, has a prevalence of one in every 2,500–7,000 people. This condition is one of the leading causes that leads to blindness in patients in the age range of 20–60 years old.

Stargardt disease is the most common inherited single-gene retinal disease. In terms of the first description of the disease, it follows an autosomal recessive inheritance pattern, which has been later linked to bi-allelic ABCA4 gene variants (STGD1). However, there are Stargardt-like diseases with mimicking phenotypes that are referred to as STGD3 and STGD4, and have a autosomal dominant inheritance due to defects with ELOVL4 or PROM1 genes, respectively. It is characterized by macular degeneration that begins in childhood, adolescence or adulthood, resulting in progressive loss of vision.

A visual prosthesis, often referred to as a bionic eye, is an experimental visual device intended to restore functional vision in those with partial or total blindness. Many devices have been developed, usually modeled on the cochlear implant or bionic ear devices, a type of neural prosthesis in use since the mid-1980s. The idea of using electrical current to provide sight dates back to the 18th century, discussed by Benjamin Franklin, Tiberius Cavallo, and Charles LeRoy.

<span class="mw-page-title-main">Foundation Fighting Blindness</span>

The mission of the Foundation Fighting Blindness is to fund research that will lead to the prevention, treatment and cures for the entire spectrum of retinal degenerative diseases, including retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease and related conditions. These diseases, which affect more than 10 million Americans and millions more throughout the world, often lead to severe vision loss or complete blindness.

Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness.

Neurostimulation is the purposeful modulation of the nervous system's activity using invasive or non-invasive means. Neurostimulation usually refers to the electromagnetic approaches to neuromodulation.

<span class="mw-page-title-main">Photovoltaic retinal prosthesis</span>

Photovoltaic retinal prosthesis is a technology for restoration of sight to patients blinded by degenerative retinal diseases, such as retinitis pigmentosa and age-related macular degeneration (AMD), when patients lose the 'image capturing' photoreceptors, but neurons in the 'image-processing' inner retinal layers are relatively well-preserved. This subretinal prosthesis is designed to restore sight by electrically stimulating the surviving inner retinal neurons, primarily the bipolar cells. Photovoltaic retinal implants are completely wireless and powered by near-infrared illumination (880 nm) projected from the augmented-reality glasses. Lack of trans-scleral cable greatly simplifies the implantation procedure compared to other retinal implants. Optical activation of the photovoltaic pixels allows scaling the implants to thousands of electrodes and retains natural coupling of the eye movements to visual perception. Studies in rats with retinal degeneration demonstrated that prosthetic vision with such subretinal implants preserves many features of natural vision, including flicker fusion at high frequencies (>20 Hz), adaptation to static images, antagonistic center-surround organization and non-linear summation of subunits in receptive fields, providing high spatial resolution.

<span class="mw-page-title-main">Retinal regeneration</span>

Retinal regeneration refers to the restoration of vision in vertebrates that have suffered retinal lesions or retinal degeneration.

José-Alain Sahel is a French ophthalmologist and scientist. He is currently the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Vision Institute, and the Eye and Ear Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute in Paris, a research center associated with one of the oldest eye hospitals of Europe - Quinze-Vingts National Eye Hospital in Paris, founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies. He is a member of the French Academy of Sciences.

<span class="mw-page-title-main">Applied Genetic Technologies Corporation</span> Biotechnology company

The Applied Genetic Technologies Corporation is a publicly traded biotechnology company that is part of the NASDAQ Biotechnology Index. It was founded in 1999 and has its headquarters in Alachua, Florida. In late June 2019, the company announced the appointment of Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah, M.D., M.B.A., to Join as Chief Medical Officer.

Mark S. Humayun is a Pakistani-American ophthalmologist, engineer, scientist, inventor and academic – the only ophthalmologist elected a member of both U.S. National Academies of Medicine and Engineering. He is a university professor with joint appointments at the Keck School of Medicine of USC and the USC Viterbi School of Engineering.

<span class="mw-page-title-main">Robert MacLaren</span> British ophthalmologist

Robert E. MacLaren FMedSci FRCOphth FRCS FACS VR is a British ophthalmologist who has led pioneering work in the treatment of blindness caused by diseases of the retina. He is Professor of Ophthalmology at the University of Oxford and Honorary Professor of Ophthalmology at the UCL Institute of Ophthalmology. He is a Consultant Ophthalmologist at the Oxford Eye Hospital. He is also an Honorary Consultant Vitreo-retinal Surgeon at the Moorfields Eye Hospital. MacLaren is an NIHR Senior Investigator, or lead researcher, for the speciality of Ophthalmology. In addition, he is a member of the research committee of Euretina: the European Society of Retina specialists, Fellow of Merton College, in Oxford and a Fellow of the Higher Education Academy.

<span class="mw-page-title-main">Wolfgang Fink</span> German-American theoretical physicist

Wolfgang Fink is a German-American theoretical physicist. He is currently an associate professor and the inaugural Maria & Edward Keonjian Endowed Chair of Microelectronics at the University of Arizona. Fink has joint appointments in the Departments of Electrical & Computer Engineering, Biomedical Engineering, Systems & Industrial Engineering, Aerospace & Mechanical Engineering, and Ophthalmology & Vision Science at the University of Arizona. He is the current Vice President of the Prognostics and Health Management (PHM) Society.

Voretigene neparvovec, sold under the brand name Luxturna, is a gene therapy medication for the treatment of Leber congenital amaurosis.

References

  1. ↑ Renaissance Capital (19 November 2014). "Second Sight sees double: Year's 6th IPO to soar 100% on day one" . Retrieved 10 February 2023.
  2. 1 2 Their Bionic Eyes Are Now Obsolete and Unsupported, by Eliza Strickland and Mark Harris, in IEEE Spectrum ; published 15 February 2022; retrieved 17 February 2022
  3. ↑ Harris, Mark. "Second Sight's Implant Technology Gets a Second Chance - IEEE Spectrum". IEEE . Retrieved 18 August 2023.
  4. 1 2 3 4 5 6 7 Chuang, AT; Margo, CE; Greenberg, PB (July 2014). "Retinal implants: a systematic review". The British Journal of Ophthalmology. 98 (7): 852–6. doi:10.1136/bjophthalmol-2013-303708. PMID   24403565. S2CID   25193594.
  5. 1 2 3 4 5 "IPG519: Interventional procedure overview of insertion of an epiretinal prosthesis for retinitis pigmentosa". National Institute for Health and Care Excellence Interventional Procedures Programme. Updated December 2014. Retrieved 4 September 2015.
  6. ↑ "FDA clears Argus II 'bionic eye' for sale in the US (video)". Engadget. 15 February 2013. Retrieved 17 February 2013.
  7. ↑ "Argus II Retinal Prosthesis System Doctors Users Manual" (PDF). FDA. 29 July 2013. Retrieved 11 December 2019.
  8. ↑ Ronald D. White. "With 'bionic eye' booming, Second Sight is on analysts' radar". Los Angeles Times . 16 March 2015. Retrieved 4 September 2015.
  9. 1 2 Duncan Graham-Rowe. "Visions of the future". Wired UK . 6 August 2010. Retrieved 4 September 2015.
  10. ↑ Chris Wiltz. "Argus II Bionic Eye Gives Second Sight to the Blind". Medical Device & Diagnostic Industry. 6 March 2013. Retrieved 4 September 2015.
  11. 1 2 3 Noel McKeegan. "Second Sight announces milestone in groundbreaking retinal implant trial". Gizmag. 19 February 2008. Retrieved 4 September 2015.
  12. ↑ "A Bionic Eye That Restores Sight". The Atlantic . 31 August 2014. Retrieved 5 January 2015.
  13. 1 2 "A Bionic Eye Comes to Market". MIT Technology Review . 7 March 2011. Archived from the original on 29 January 2013. Retrieved 17 February 2013.
  14. ↑ "FDA approves first retinal implant for rare eye disease". Reuters . 14 February 2013. Retrieved 14 February 2013.
  15. ↑ "FDA approves first retinal implant for adults with rare genetic eye disease". Food and Drug Administration. 14 February 2013. Retrieved 5 January 2015.
  16. ↑ Pam Belluck. "Device Offers Partial Vision for the Blind". The New York Times . 15 February 2013. Retrieved 4 September 2015.
  17. ↑ "Medicare Designates Argus® II Retinal Prosthesis System as New Technology and Provides Payment" Archived 2 February 2019 at the Wayback Machine . Second Sight. 15 August 2013. Retrieved 4 November 2013.
  18. ↑ "Blind NHS patients to get bionic eyes". IT Pro. 22 December 2016. Retrieved 22 December 2016.
  19. ↑ "Second Sight's Implant Technology Gets a Second Chance - IEEE Spectrum".
  20. ↑ "Second Sight Agrees to Merger to Maintain Retinal and Cortical Prostheses Programs".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.